We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Proposes Reporting Leeway During Flu Pandemics
FDA Proposes Reporting Leeway During Flu Pandemics
January 7, 2009
Drugmakers should develop plans to ensure postmarketing adverse event reports are prepared and submitted regularly during an influenza pandemic, the FDA proposes.